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We expanded GWAS discovery for type 2 diabetes (T2D) by combining data from 898,130 
European-descent individuals (9% cases), following imputation to high-density reference 
panels. With these data, we: (a) extend the inventory of T2D-risk variants (243 loci, 135 
newly-implicated in T2D-predisposition, comprising 403 distinct association signals); (b) 
enrich discovery of lower-frequency risk-alleles (80 index variants with minor allele 
frequency <5%, 14 with estimated allelic odds-ratio >2); (c) substantially improve fine-
mapping of causal variants (at 51 signals, one variant accounted for >80% posterior 
probability of association (PPA)); (d) extend fine-mapping through integration of tissue-
specific epigenomic information (islet regulatory annotations extend to 73 the number of 
variants with PPA>80%); (e) highlight validated therapeutic targets (18 genes with 
associations attributable to coding variants); and (f) demonstrate enhanced potential for 
clinical translation (genome-wide chip heritability explains 18% of T2D-risk; individuals in 
the extremes of a T2D polygenic risk score differ >9-fold in prevalence).  
 
Array-based genome-wide association studies (GWAS) have identified ~140 loci influencing 
risk of type 2 diabetes (T2D)1-3. Follow-up of these genetic discoveries has been 
compromised by the incomplete coverage of the most frequently-used genotyping arrays, 
imperfect performance of the reference panels available for imputation, extensive local 
linkage disequilibrium (LD), and inadequate sample sizes. These have combined to reduce 
power to detect low-frequency alleles with population-scale impact, to deliver clinically-
relevant risk prediction, and to define molecular mechanisms involved in disease 
predisposition. Here, we address the limitations of previous studies by combining GWAS 
from ~900,000 Europeans with dense, high-quality imputation, producing the most 
comprehensive view to date of the genetic contribution to T2D with respect to locus 
discovery, causal variant resolution, and mechanistic insight. 
 
RESULTS 
 
Study overview. We combined data from 32 GWAS, including 74,124 T2D cases and 824,006 
controls of European ancestry (effective sample size [Neff] 231,436). This represents a 3.2-
fold increase in Neff from the largest previous genome-wide study of T2D-risk in Europeans1. 
After harmonised quality control, 31 of the 32 GWAS were imputed using 64,976 whole-
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genome sequenced haplotypes from the Haplotype Reference Consortium (HRC)4: the 
exception was the deCODE GWAS, imputed using a population-specific reference panel of 
30,440 Icelandic haplotypes5 (Methods, Supplementary Table 1). We conducted T2D 
association analyses with and without adjustment for body-mass index (BMI). 
 
Discovery of novel loci for T2D susceptibility. We tested for T2D association with ~27M 
variants passing quality control filters, ~21M having minor allele frequency (MAF)<5%. Our 
meta-analysis identified variants at 231 loci reaching genome-wide significance (p<5x10-8) in 
the BMI-unadjusted analysis (Neff 231,436) and 152 in the smaller (Neff 157,401) BMI-
adjusted analysis. Of the 243 loci identified across these two analyses, 135 mapped outside 
regions previously-implicated in T2D-risk (Methods, Figure 1, Supplementary Table 2). 
 
Amongst samples not included in previous discovery efforts (42,734 cases, 497,261 
controls), we replicated associations (directionally-consistent, p<0.05) at 126 of 140 
previously-reported T2D loci, including all 106 regions first discovered in European-only or 
trans-ethnic efforts3,6-8 and 20 initially reported in studies of non-European individuals9,10. 
The 14 loci not replicated were all first-identified in non-European ancestry samples: at five, 
the reported lead variant had MAF<1% in Europeans. 
 
Multiple association signals at T2D susceptibility loci. Across the 243 associated loci, we 
identified 160 additional signals at “locus-wide” significance (p<10-5; Methods), 110 within 
previously-reported T2D loci. Overall, we observed one signal at 151 loci, and two to ten 
signals at the remaining 92 (Supplementary Table 2), for a total of 403 distinct T2D-
association signals. 
 
We observed the first evidence for multiple signals at the TCF7L2 locus. In addition to 
rs7903146, the largest-effect common variant signal for T2D in Europeans, we detected 
seven secondary signals, each represented by non-coding index variants (0.5%<MAF<47.6%, 
1.05<odds-ratio [OR]<1.36). 
 
In the ~1Mb telomeric region of chromosome 11 that encompasses the (previously-
annotated) INS-IGF2 and KCNQ1 loci, we detected 15 distinct signals (0.15%<MAF<42.8%, 
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1.03<OR<1.68). This multiplicity of signals in a region notable for complex imprinting effects, 
and several strong biological candidates (INS, IGF2, KCNQ1, CDKN1C), illustrates a 
previously-unrecognised degree of complexity in the risk-variant architecture at this locus. 
 
The effects of BMI and sex. At most T2D-loci, there were only minimal differences in 
estimated T2D effect size between BMI-adjusted and unadjusted models (Methods, Figure 
2). However, at index SNPs for 41 signals (mapping to 21 known and 16 novel loci), we 
observed significant differences in effect sizes between BMI-adjusted and unadjusted 
analyses (pdiff<0.00012, corrected for 403 variants; Methods, Supplementary Table 3, Figure 
2). This effect-size heterogeneity followed two distinct patterns. At 26 signals, including 
index variants for signals at the FTO, MC4R, TMEM18, SEC16B, and GNPDA2 loci, BMI-
adjustment produced marked attenuation of associations detected in unadjusted analysis. 
These signals display positive correlations between BMI and T2D effect sizes, and represent 
T2D-risk effects primarily driven by adiposity. The other 15 signals were more strongly-
associated in the BMI-adjusted analysis, and reflect a mixture of associations, some with a 
marked effect on insulin secretion (e.g. TCF7L2, ARAP1, JAZF1), and others that likely 
influence T2D-risk through reduced capacity for fat storage in peripheral adipose tissue11 
(e.g. GRB14, PPARG, HMGA1, ZNF664). 
 
In comparative analysis of T2D effects in males (41,846 cases, 383,767 controls) and females 
(30,053 T2D cases, 434,336 controls; Methods)12, only one of the 403 T2D signals showed 
significant (pdiff<0.00012) differences in effect size (rs2925979 near CMIP, female OR=1.09, 
male OR=1.03, pdiff=8.3x10-6; Supplementary Figure 1, Supplementary Table 4). We 
observed nominally-significant differences at several other loci, including KLF14 (rs1562396, 
female OR=1.09, male OR=1.04, pdiff=0.00048) at which there is additional corroboration for 
sex-specific effects,13,14 indicating that additional examples of sex-differentiated signals are 
likely to be found in larger samples. 
 
Fine-mapping variants driving T2D association signals. Previous efforts at fine-mapping 
causal variants within T2D loci have been hampered by both biological (extensive LD) and 
technical (diverse genotyping scaffolds, incomplete reference panels) factors. We sought to 
establish the extent to which the combination of increased sample size, enlarged reference 
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panel, and harmonised variant quality control would enhance fine-mapping resolution. We 
were able to undertake fine-mapping for 380 of the 403 distinct T2D association signals, 
following conditional decomposition of loci with multiple signals (Methods). For each, we 
constructed credible sets that collectively account for ≥99% of the posterior probability of 
association (PPA; Methods)15. These credible sets included a median of 42 variants (range 1-
3997; Supplementary Figure 2), and spanned a median of 116kb (range 1bp-995kb). At 51 
signals, involving 44 loci (18 novel), the most strongly-associated variant accounted for 
>80% PPA (Figure 3, Supplementary Table 5). At 18, the credible set included a single 
variant (PPA>99%). 
 
We explored fine-mapping resolution at 83 distinct signals where detection in both studies 
allowed us to compare 99% credible sets from the HRC-based analysis with those 
constructed in a subset of these T2D GWAS imputed using the 1000 Genomes Project multi-
ethnic reference panel1 (26,676 T2D cases; 132,532 controls of European ancestry, Neff 
72,143). Although the former includes 2.3-fold more variants genome-wide than the latter, 
the HRC-imputed analysis resulted in smaller credible sets. The median number of variants 
at these 83 signals decreased from 59 to 10 and interval length from 60.3kb to 19.2kb. At 79 
of 83 signals, HRC-based credible sets were either smaller than those generated from 1000G 
or unchanged (Figure 4, Supplementary Table 6). 
 
This improved resolution likely reflects the combination of: (i) increased Neff; (ii) improved 
imputation quality, especially for lower-frequency variants4; and (iii) more effective, 
harmonised, quality control across contributing studies (Methods). To estimate the 
contribution to fine-mapping resolution attributable to the increase in Neff (the other factors 
are more difficult to tease apart), we constructed 99% credible sets based on downscaling 
the HRC-imputation to a subset of 19 studies (31,387 cases; 326,742 controls, Neff 92,960) 
that contributed to both 1000G and HRC-based analyses. Amongst 41 single signal loci with 
p<1x10-5 in this downscaled meta-analysis, estimates of credible set size (median 66) and 
interval (median 196kb) indicate that the improvements in causal variant resolution derive 
mostly from increased sample size. 
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The HRC panel provides excellent coverage of all but very rare SNVs. However, one HRC 
limitation is the absence of indels: these constitute 4% of total variants in the phase 3 
1000G reference panel16. We considered the 245,207 indels from the European subset of 
the 1000G panel which map within 500kb of index variants at the 380 fine-mapped signals: 
these account for 2.8% of variants across the 380Mb of sequence. Only 1% of these are in 
even moderate LD (r2>0.5) with index variants for each T2D-association signal, indicating 
that indel omission is likely to have limited impact on our estimates of credible set size. 
 
The contribution of lower-frequency variants. The limited yield of low-frequency and rare 
variant signals in previous T2D GWAS placed an upper bound on their individual and 
collective contribution to disease-risk17. The present analysis, with larger sample size and 
improved imputation, provides greater power in this regard, identifying 56 low-frequency 
and 24 rare T2D-associated variants across 60 loci (Figure 5). Six of these 80 signals mapped 
within known T2D loci, five reconfirming earlier observations (Supplementary Table 2). 
 
Allelic OR for low-frequency and rare variants ranged from 1.08-8.05 (including 14 with 
estimated allelic OR>2; at each, the minor allele conferred T2D-risk), compared with 1.03-
1.37 for common variants (Figure 5). The 80 lower-frequency risk-variants cumulatively 
explained 1.1% of phenotypic variance in T2D, compared to 16.3% attributable to the 323 
common-variant signals (Methods). Extrapolation beyond these discovered signals to 
estimate the full contribution of lower-frequency variants to T2D-risk is intrinsically difficult 
given the combination of effect-size overestimation and limited power to capture lower-
frequency variants of lesser effect. Nonetheless, these data are consistent with recently-
proposed models for the genetic architecture of T2D based on GWAS and sequencing 
data17. Notwithstanding, the identification of lower-frequency variants of modest to large 
effect can provide valuable biological inference, and we briefly describe some of these 
signals. 
 
We observed a mix of common and low-frequency variant signals around NEUROG3, 
including T2D-risk attributable to the minor alleles at rs41277236 (p.Gly167Arg, MAF=4.3%, 
OR=1.09, p=1.5x10-6) and rs549498088 (non-coding, MAF=0.60%, OR=1.56, p=4.7x10-7). 
NEUROG3 encodes the neurogenin-3 transcription factor implicated in pancreatic islet and 
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enteroendocrine cell development18. Rare homozygous, hypomorphic missense mutations 
in NEUROG3 (non-overlapping with those we detected) are a cause of childhood-onset 
diabetes associated with severe malabsorptive diarrhea19. Age of T2D-diagnosis amongst 
carriers of these low-frequency T2D-risk alleles was, in UK Biobank, similar to non-carriers 
(rs41277236: 52.3 vs 52.7 years, p=0.21; rs549498088: 51.1 vs 52.7 years; p=0.49), 
consistent with a spectrum of functional impact that associates these variants with typical 
T2D. In UK Biobank, T2D-risk alleles at NEUROG3 were associated with phenotypes 
recapitulating the gastrointestinal component of the neonatal syndrome (including 
“obstruction of bile duct” [OR=1.29; p=0.023], “gastrointestinal complications” [OR=1.79; 
p=0.024], and “functional digestive disorders” [OR=1.06; p=0.027]). 
 
We detected two previously-unreported rare alleles with large ORs. The first was intronic to 
DENND2C (rs184660829, MAF=0.020%, OR=8.1, p=2.5x10-8). In exploratory analyses within 
UK Biobank, the T2D-risk allele was associated with “lower gastrointestinal congenital 
anomalies” (OR=17.3 p=0.00047). The second mapped near KIF2B (rs569511541, 
MAF=0.020%, OR=7.6, p=1.5x10-8) and was also associated with “congenital anomalies of 
endocrine gland” (OR=30.8; p=0.00015), “disease of pancreas” (OR=5.9; p=0.0017), and 
“hypokalemia” (OR=6.9; p=0.0046). Both sites are present in the Genome Aggregation 
Database (gnomAD)20 and met quality control criteria in our data (average imputation 
quality >0.7; association signal visible in multiple studies), but their precise contribution to 
T2D-risk requires further validation.  
 
Causal coding variants. We next considered the 51 signals (of 380) where fine-mapping 
strongly implicated (PPA>80%) a single causal variant. Eight of these were missense coding 
variants, six of which fell into established T2D-associated regions (Supplementary Table 7). 
With the exception of p.Cys130Arg at APOE (MAF=15.4%), all have been previously-
implicated as causal for T2D: p.Ser539Trp in PAM (MAF=0.83%); p.Thr139Ile in HNF4A 
(MAF=3.5%); p.Asp1171Asn in RREB1 (MAF=11.3%); p.Ala146Val in HNF1A (MAF=2.9%); and 
p.Pro446Leu in GCKR (MAF=39.3%)3. Coding variant associations at PATJ (p.Gly157Val; 9.5% 
MAF) and CDKN1B (p.Val109Gly; 23.5% MAF) are novel and highlight these genes as playing 
direct roles in T2D-risk. PATJ is highly expressed in brain21 and encodes Pals1-Associated 
Tight Junction component, a protein with multiple PDZ domains that mediate protein-
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protein interactions. Associations for this variant indicate a central mechanism of action: the 
T2D-risk allele is associated with obesity in UK Biobank (OR=1.11; p=3.8x10-5) and the T2D-
association signal is attenuated in BMI-adjusted analysis (pdiff=9.3x10-10). CDKN1B encodes a 
cyclin dependent kinase inhibitor: in mouse, deletion of this gene ameliorates 
hyperglycemia by increasing islet mass and maintaining compensatory hyperinsulinemia22. 
There were a further four signals (at ANKH, POC5, NEUROG3, and ZNF771) at which a single 
missense variant accounted for the majority (>50%) of the PPA (Supplementary Table 7).  
 
Integration of regulatory annotations to support fine-mapping. Of the 51 variants with 
PPA>80%, 43 mapped to regulatory sequence: 12 of these were low-frequency or rare, 
including variants near ANKH, CCND2, and WDR72. To characterise the regulatory impact of 
these 51 variants, we overlaid them onto chromatin-state maps from T2D-relevant tissues 
(islets, liver, adipose, skeletal muscle23-25) and transcription factor binding sites23,24. Twenty-
eight mapped to islet enhancer or promoter elements; for 14, these chromatin states were 
islet-specific (Supplementary Table 8, Supplementary Figure 3). These data recapitulate 
previous findings implicating islet regulatory mechanisms at the CDC123-CAMKD1 
(rs11257655) and MTNRB1 (rs10830963)25-27, and indicate that similar molecular 
mechanisms operate at signals for several other known T2D loci, including IGF2BP2, ANK1, 
GLIS3, CDKN2B, KCNQ1, CCND2, and BCL2A. Novel T2D signals near ABCB10, FAM49A, 
LRFN2, CRHR2, and CASC11 also overlapped islet-specific enhancers or promoters. High-PPA 
(i.e. PPA>80%) variants at 13, 10, and 7 signals overlapped enhancers or promoters in 
adipose, skeletal muscle, and liver, respectively. All but four of these were also enhancers or 
promoters in islets: one signal (near GLI2) mapped to an adipose-specific enhancer, another 
(near WDR72) to a liver-specific enhancer, and two (near PTGFRN and TSC22D2) to 
enhancers in both adipose and skeletal muscle. 
 
We next evaluated whether the integration of genome-wide regulatory annotation data 
could refine mapping resolution at those loci where genetic fine-mapping was less precise25. 
We focused on regulatory annotations from human islets because: (a) most established 
T2D-risk variants are considered, given patterns of association to continuous metabolic 
traits, to act through primary effects on beta-cell function3,28,29; (b) the strongest signal for 
regulatory enrichment at T2D association signals involves islet-specific regulatory 
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elements23,26, a view supported by the annotation overlaps of the high-PPA variants 
described above, and by enrichment analyses we performed using epigenomic annotations 
from islets, fat, muscle, and liver24 (Supplementary Figure 4); and (c) we had access to high-
resolution epigenomic and chromatin state annotation maps for human islets combining 
available histone modification and transcription factor ChIP-seq, ATAC-seq and whole 
genome bisulphite sequencing25. 
 
Using the hierarchical modelling approach fGWAS30, genome-wide, we observed strong (1.9-
8.2 fold), significant (95% confidence not overlapping one) enrichment of T2D-associated 
variation with respect to multiple islet enhancer and promoter states, as well as coding 
sequence (with concomitant depletion of heterochromatin states; Methods, 
Supplementary Figure 5). We used the parameter estimates from the joint annotation 
model (which retained islet enhancers, promoters, and coding sequence, amongst other 
annotations; Methods, Supplementary Figure 5) as priors to redefine 99% credible sets for 
the 380 distinct T2D association signals amenable to fine-mapping. We circumvented the 
default assumption in fGWAS of a single casual variant per locus by conducting these 
analyses on conditionally-decomposed data (noting that this does still allow for the 
possibility that the association at each conditional signal is distributed across multiple 
variants on a risk haplotype; Methods). 
 
As expected, this integrated fine-mapping analysis boosted PPA for variants overlapping 
enriched annotations (Figure 6). The median 99% credible set size declined from 42 to 32, 
credible intervals from 116kb to 100kb, and maximum variant PPA per signal climbed by a 
median of 21%. The number of signals at which the lead variant PPA exceeded 80% 
increased from 51 to 73, with dramatic improvements at some (e.g. at GNG4 where the PPA 
for rs291367 rose from 24.0% to 84.2%; Figure 3). 
 
These annotation-supported analyses highlighted seven additional loci (further to the 12 
from genetic evidence alone) where the majority of the PPA was invested in a coding variant 
(Supplementary Table 7). Four were novel: QSER1 (p.Arg1101Cys; MAF=4.3%), SCD5 
(p.Glu197Gln, MAF=33.8%), IRS2 (p.Gly1057Asp, MAF=34.0%) and MRPS30 
(p.Glu128Gln=MAF 2.8%). 
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In our recent study of exome-array genotypes, we demonstrated that, for one-third of loci 
harbouring coding variant associations, a causal role could be excluded once information on 
local LD and annotation enrichment was incorporated3. For all 19 coding variant signals (at 
18 loci) described in this study, present analyses (based on genome-wide data for both 
discovery and fine-mapping) were consistent with a causal role. These analyses therefore 
provide additional examples of human validated targets31. The value of these targets as 
leads to therapeutic development will ultimately depend not only on their impact on T2D 
phenotypes, but also on the consequences of perturbation on other traits, including 
coronary artery disease (CAD). Among the 19 T2D-associated coding variants, nine were also 
nominally associated (p<0.05) with CAD32: at three (APOE, GCKR, and RREB1) opposing 
effects on T2D- and CAD-predisposition render them less attractive targets (Supplementary 
Table 7). 
 
Next, we concentrated on non-coding variant signals. In the annotation-informed analysis, 
we identified 15 additional signals (beyond the 43 non-coding signals described above) at 
which the lead variant PPA exceeded 80% (Supplementary Table 8). These signals overlap 
active islet regulatory sites including strong enhancers (e.g. at TCF7L2, HNF4A, ANKH, RNF6, 
ZBED3), active promoters (EYA2), weak enhancers (ADSCL2, ADCY5, CDKN2B, TBCE), and 
weak promoters (DGKB). For many, orthogonal data (e.g. associations with continuous 
metabolic traits3,28,29, cis-eQTL data33; Supplementary Table 8) are consistent with a role in 
islet function. In contrast, at six signals, including three that are likely, on physiological 
grounds, to be acting, at least partly, through effects on islets, we saw reductions (10% to 
76%) in the lead variant PPA after islet-annotation-informed fGWAS (Supplementary Table 
8). This occurred when lead variants from the genetic fine-mapping overlapped annotations 
depleted in the genome-wide model. Examples include variants at primary CDKAL1 and 
secondary KCNQ1 and INS-IGF2 signals, where the index-variant PPA decreased by 76% 
(rs7756992), 34% (rs2283164), and 22% (rs555759341), respectively. One explanation is that 
these represent T2D-association signals where the phenotypic impact on insulin secretion is 
mediated through long-term consequences of regulatory effects during islet development 
which are no longer reflected in regulatory annotations seen in mature islets.  
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At many of these fine-mapped regulatory loci, the integrated data provide novel insights 
into disease mechanisms: here, we highlight three. At ST6GAL1, rs3887925 achieves 
PPA=98.5% through genetic fine-mapping alone (99.3% in fGWAS), and overlaps enhancers 
active in islet, as well as liver, adipose, and skeletal muscle (Supplementary Figure 6). 
However, the T2D-risk allele at rs3887925 is associated with an increase in ST6GAL1 cis-
expression specific to islets33 (Methods, Supplementary Table 8), consistent with evidence 
for reduced insulin secretion in risk-allele carriers during provocative testing34. The 
candidate effector transcript, ST6GAL1, encodes β-galactoside α2,6-sialyltransferase-1, a key 
enzyme responsible for the biosynthesis of α2,6-linked sialic acid in N-linked glycans. Altered 
glycosylation has the potential to impact multiple processes, and global perturbation of 
ST6GAL1 has broad effects including, in St6gal1 knockout mice, increased body weight and 
visceral fat accumulation35. However, no equivalent association between rs3887925 and 
anthropometric and lipid phenotypes is seen in human GWAS14,36,37. This is consistent with 
T2D-predisposition attributable to rs3887925 being mediated through regulatory 
mechanisms restricted to the modulation of ST6GAL1 expression in islets. 
 
At ANK1, we observed three distinct association signals. The strongest causal variant 
attribution was for the primary signal at rs13262861 (PPA=97.3% on genetic data alone; 
98.8% with fGWAS). This variant overlaps an islet promoter located 3’ to ANK1 and 5’ to the 
transcription factor NKX6.3 (Supplementary Figure 7). The T2D-risk allele at rs13262861 
shows a directionally-consistent association with in vivo measures of reduced insulin 
secretion3,29,34, and a cis-eQTL for reduced NKX6-3 expression in human islets 
(Supplementary Table 8). Members of the NKX6 family (including NKX6.3) are implicated in 
islet development and function38. A recent study highlighted the relationship between 
variants including rs515071 and rs508419 and the expression and splicing of ANK1 in 
skeletal muscle39. However, in our meta-analysis, variants influencing ANK1 splicing have 
minimal impact on T2D-risk (PPA<1% in all three conditionally-decomposed signals [genetic 
fine-mapping only]). Collectively, these data indicate that the mechanism of T2D 
predisposition at this locus is more likely mediated through reduced islet expression of 
NKX6.3 than altered muscle expression of ANK1. 
 
19 
 
At TCF7L2, patterns of overlap with epigenomic annotations across the eight distinct T2D-
association signals offer explanations for the diverse metabolic consequences of TCF7L2 
perturbation in humans and animal models (Supplementary Table 9)40. The primary signal 
at rs7903146, long-established as the largest common variant effect for T2D in Europeans, 
overlaps an islet enhancer (boosting PPA from 59.2% to 97.1% on fGWAS), multiple islet-
relevant transcription factor binding sites, and islet open chromatin41, all features consistent 
with the islet phenotype (deficient insulin secretion) evident in non-diabetic individuals7 
(Supplementary Figure 8). However, amongst the seven secondary signals, the picture is 
more mixed. Of the four secondary signals mapped to <10 credible set variants, only 
rs144155527 rises to moderate PPA (68%) following islet annotation-enriched fGWAS 
analysis. Other credible set variants map to adipose and liver enhancers, suggesting that 
their T2D-risk effects are mediated via modulation of TCF7L2 expression in tissues relevant 
to insulin action. 
 
Heritability estimates and polygenic risk score prediction. Using LD score regression42, and 
empirical estimates of population- and sample-level T2D prevalence, we estimated chip 
heritability (on the liability scale) for T2D at 18% (23% in females and 17% in males; 
Supplementary Figure 9), accounting for approximately half the median estimates of 
heritability derived from twin and family studies43.  
 
Identification of individuals at increased genetic risk for T2D could enhance screening 
strategies and allow targeted prevention. Previous attempts to deploy genetic data for 
disease prediction have shown limited utility44,45. We used a revised BMI-unadjusted meta-
analysis, generated from all samples other than UK Biobank, to develop genome-wide 
polygenic risk scores (PRS)46 which we then applied to predict T2D status in the 18,197 cases 
and 423,697 controls from UK Biobank (Europeans only; Methods). Maximal discrimination 
(AUC C-statistic of 66%, equivalent to that derived from BMI, age, and sex in the same 
sample) was obtained from a PRS of 136,795 variants (r2>0.6, p<0.076; Supplementary 
Figure 10). Individuals in the top 2.5% of the PRS distribution were at 3.4-fold increased risk 
(prevalence=11.2%) compared to the median (prevalence=3.3%), and 9.4-fold compared to 
the bottom 2.5% (prevalence=1.2%). Low T2D prevalence rates in UK Biobank reflect the 
age-distribution of the cohort and preferential ascertainment of healthy individuals: 
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however, similar prevalence ratios were observed in the subset of individuals aged >55 
years at recruitment (14.2% vs 1.6%). Applied to the general UK population, equivalent 
performance would equate to lifetime risks for T2D of ~59.7% and ~6.7% for individuals 
from those extremes, based on current UK general population prevalence rates for those 
>55 years of age47. 
 
Defining relationships with other traits. To characterise genetic relationships with other 
biomedical-relevant traits, we used LD score regression42 as implemented in LDHub48. We 
tested 182 unique phenotypes, after excluding those with low heritability estimates and 
repeated measures. Eighty-five traits demonstrated a significant (Bonferroni corrected 
threshold p<0.00027) genetic correlation with T2D (Supplementary Table 10, 
Supplementary Figure 11).  
 
These highlighted several interesting genetic correlations, linking increased T2D-risk to 
sleeping behaviours (insomnia, excessive daytime sleeping), smoking (cigarettes smoked per 
day, ever versus never smoked), metabolites (glycoprotein acetyls, isoleucine, valine), 
depressive symptoms, urinary albumin-to-creatinine ratio, and urate. T2D-risk was 
negatively correlated with anorexia nervosa, intelligence, parent’s age at death, lung 
function measures, education status/duration, age at menarche, and age of mother at first 
childbirth. Many of these relationships (including those related to intelligence, smoking 
behaviour, age at menarche, and education status) were primarily mediated by the shared 
impact of BMI/obesity on both T2D and the correlated phenotype (Supplementary Figure 
12). 
 
DISCUSSION 
 
This study demonstrates how substantial increases in sample size coupled to more accurate 
and comprehensive imputation expand characterization of the genetic contribution to T2D-
risk. The number of significantly-associated genomic regions has doubled, with a growing 
harvest of risk-alleles of lower-frequency, some with relatively large effects. At many of 
these signals, fine-mapping resolution has been substantially improved: we mapped 51 of 
380 signals to single-variant resolution on genetic evidence alone, and demonstrated that 
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the integration of genomic annotations (here focused on the human islet epigenome) 
provides further specification of plausible causal variants. We highlight 18 genes as human 
validated targets based on causal coding variants and provide novel insights into the 
biological mechanisms operating at several fine-mapped regulatory signals. These findings 
represent mechanistic hypotheses that can now be targeted for large-scale empirical 
validation at both the level of the variants (e.g. through massively parallel reporter assays) 
and the candidate effector genes (e.g. through CRISPR screens in appropriate cellular 
models, and manipulation in in vivo models). The present study was limited to individuals of 
European ancestry: integration of these data with large-scale GWAS data from other major 
ancestral groups (as is being pursued by the DIAMANTE consortium) should provide an 
additional boost to locus discovery, and support further increases in causal variant 
resolution, most obviously at loci where extensive LD within Europeans limits resolution of 
fine-mapping.  
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FIGURE LEGENDS 
 
Figure 1 | Manhattan plots of the sex-combined BMI-unadjusted and adjusted meta-
analysis for T2D. a, Manhattan plot (top panel) of genome-wide association results for T2D 
without BMI adjustment from meta-analysis of up to 71,124 cases and 824,006 controls. 
The association p-value (on -log10 scale) for each SNP (y-axis) is plotted against the genomic 
position (NCBI Build 37; x-axis). Association signals that reached genome-wide significance 
(p<5x10-8) are shown in purple if novel. b, Manhattan plot (bottom panel) of genome-wide 
association results for T2D with BMI adjustment from meta-analysis of up to 50,409 cases 
and 523,897 controls. Novel association signals that reached genome-wide significance 
(p<5x10-8) only in the BMI-unadjusted analysis are shown in orange. 
Figure 2 | Comparison of estimated T2D effect size between BMI-adjusted and unadjusted 
models. Z-score for each of the 403 distinct signals from BMI-unadjusted analysis (50,791 
cases and 526,121 controls; x-axis) is plotted against the z-score from the BMI-adjusted 
analysis (50,402 cases and 523,888 controls; y-axis). Variants that display higher T2D effect 
size in BMI-adjusted analysis are shown in red and variants with higher T2D effects in BMI-
unadjusted analysis are shown in blue. Diameter of the circle is proportional to -log10 
heterogeneity p-value. 
Figure 3 | Summary of fine-mapped associations. a, Distinct association signals. A single 
signal at 151 loci, and 2-10 signals at 92. b, Number of variants in genetic and functional 
99% credible sets. Eighteen and 23 signals were mapped to a single variant in genetic and 
functional credible sets, respectively. c, Distribution of the posterior probability of 
association of the variants in credible sets. 
Figure 4 | Comparison of fine-mapping resolution at 83 distinct signals. The number of 
variants included in the 99% credible set for each of the 83 distinct signals constructed using 
meta-analysis of GWAS data imputed using the 1000G multi-ethnic reference panel (26,676 
T2D cases and 132,532 controls) (x-axis; logarithmic scale) is plotted against those (y-axis; 
logarithmic scale) derived using HRC-based imputation (74,124 T2D cases and 824,006 
controls). Inset presents the same plot but with linear scales.  
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Figure 5 | The relationship between effect size and minor allele frequency. Conditional and 
joint analysis effect size (y-axis) and minor allele frequency (x-axis) for 403 conditionally 
independent SNPs. Previously-reported T2D associated variants are shown in green and 
novel variants are shown in purple. Stars and circles represent the “strongest regional lead 
at a locus” and “lead variants for secondary signals”, respectively. 
Figure 6 | Comparison of posterior probability of association for each variant with and 
without incorporation enrichment information. Posterior probability of association from 
genetic credible sets (y-axis) and fGWAS analysis (x-axis) for each variant included in the 
99% credible sets. 
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ONLINE METHODS 
 
Ethics statement. All human research was approved by the relevant institutional review 
boards, and conducted according to the Declaration of Helsinki. All participants provided 
written informed consent. 
 
Study-level analyses. We considered a total of 74,124 T2D cases and 824,006 controls from 
32 GWAS undertaken in individuals of European ancestry (Supplementary Table 1), 
genotyped with a variety of genome-wide SNP arrays. Sample and variant quality control 
was performed within each study (Supplementary Table 1). To improve the quality of the 
genotype scaffold in each study, we developed a harmonised protocol in which variants 
were subsequently removed if: (i) allele frequencies differed from those for European 
ancestry haplotypes from the HRC reference panel4 by more than 20%; AT/GC variants had 
MAF>40% because of potential undetected errors in strand alignment; or (iii) MAF<1% 
because of difficulties in calling rare variants (with exception of BioMe, MGI, and UPCH, 
where no MAF exclusion was implemented as they were genotyped using newer GWAS 
arrays; Supplementary Table 1). Each scaffold, with exception of the deCODE GWAS, was 
then imputed up to the HRC reference panel4. The GWAS from deCODE was imputed up to a 
reference panel based on 30,440 Icelandic whole-genome sequences5, and only variants 
that were present on the HRC panel were considered for downstream analyses. Within each 
study, all variants were tested for association with T2D in a regression framework, with and 
without adjustment for BMI, in sex-combined and sex-specific analyses, under an additive 
model in the effect of the minor allele, with additional adjustment for study-specific 
covariates (Supplementary Table 1). To account for population structure and relatedness, 
association analyses were either adjusted for principal components (after excluding related 
individuals) or implemented in a mixed model with random effects for kinship from a 
genetic relationship matrix. For studies analysed using linear mixed models, implemented in 
EMMAX49 or BOLT-LMM50 (Supplementary Table 1), allelic effects and standard errors were 
converted to the log-odds scale to correct for case-control imbalance51. For each analysis, in 
each study, variants were removed from a study if: (i) minor allele count <5 (in cases and 
controls combined); (ii) imputation quality r2-hat<0.3 (miniMAC) or proper-info<0.4 
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(IMPUTE4); or (iii) standard error of the allelic log-OR>10. Association summary statistics for 
each analysis within each study were then corrected for residual structure by means of 
genomic control inflation factor52, calculated after excluding variants mapping to 
established T2D susceptibility loci (Supplementary Table 1).  
 
Sex-combined meta-analysis. We aggregated association summary statistics from sex-
combined analyses for each variant across studies, with and without adjustment for BMI, 
using fixed-effects meta-analysis with inverse-variance weighting of log-ORs, implemented 
in METAL53. The BMI unadjusted meta-analysis was subsequently corrected for residual 
inflation (to account for structure between studies) by means of genomic control 
(λ=1.013)52, calculated after excluding variants mapping to established T2D susceptibility 
loci. No adjustment was required for the BMI adjusted meta-analysis (λ=0.992). From the 
meta-analysis, variants were extracted that passed quality control in at least two studies. 
Heterogeneity in allelic effect sizes between studies contributing to the meta-analysis was 
assessed by Cochran’s Q statistic54. We defined novel loci as mapping >500kb and 
conditionally independent from a previously reported lead GWAS SNP.  
 
For the present study, we maintained the conventional genome-wide significance threshold 
of 5x10-8, for compatibility with previous reports. We recognise that more comprehensive 
capture of lower-frequency variants in particular increases the effective number of tests, 
with some consequent increase in the false positive rate for signals just below this 
threshold. 162 of the 243 primary signals are significant at a more stringent threshold (5x10-
9) recently advocated for whole genome sequence data55, and the major conclusions of the 
manuscript are unchanged if we select this more stringent (and given that our data lack the 
full coverage of WGS data, over-conservative) threshold. We make all summary level data 
results available so that readers can interpret the results themselves. 
 
With our sample size (Neff 231,436), assuming accurate imputation (imputation quality score 
>0.8), we had >80% power to detect T2D association (at =5x10-8) with variants of MAF≥5% 
and OR≥1.10, or MAF≥0.1% and OR≥1.60. 
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Sex-differentiated meta-analysis. The meta-analyses described above were repeated for 
males and females separately, with correction for population structure by genomic control 
as necessary: (i) male-specific BMI unadjusted λ=1.029; (ii) male-specific BMI adjusted 
λ=1.001; (iii) female-specific BMI unadjusted λ=0.955; and (iv) female-specific BMI adjusted 
λ=0.932. The male-specific meta-analysis consisted of up to 41,846 cases and 383,767 
controls, whilst the female-specific meta-analysis consisted of up to 30,053 cases and 
434,336 controls. The sex-specific meta-analyses were then combined to conduct a sex-
differentiated test of association and a test of heterogeneity in allelic effects between males 
and females12. 
 
Assessment of effect of BMI adjustment. We compared the genetic effect sizes (beta 
coefficients) estimated from models with and without BMI adjustments using a matched 
meta-analysis conducted on the same subset of 28 studies:  
 
𝛽𝑛𝑜𝐵𝑀𝐼 − 𝛽𝐵𝑀𝐼
√SE(𝛽𝑛𝑜𝐵𝑀𝐼)2 + SE(𝛽𝐵𝑀𝐼)2 − 2𝜌 × SE(𝛽𝑛𝑜𝐵𝑀𝐼) × 𝑆E(𝛽𝐵𝑀𝐼)
 
 
where 𝛽𝐵𝑀𝐼 and 𝛽𝑛𝑜𝐵𝑀𝐼 are the estimated genetic effects from models with and without BMI 
adjustment, SE(𝛽) is the estimated standard error of the estimates, and 𝜌 = 0.89, is the 
estimated correlation between 𝛽𝐵𝑀𝐼 and 𝛽𝑛𝑜𝐵𝑀𝐼 across all variants1.  
 
Detection of distinct association signals. We used GCTA56 to perform approximate 
conditional analyses to detect distinct association signals at each of the genome-wide 
significant risk loci for T2D (newly identified or confirmed, except at the major 
histocompatibility complex (MHC) region). GCTA performs conditional analysis using 
association summary statistics from GWAS meta-analysis and estimated LD from a 
sufficiently large reference study used in the meta-analysis. We used a reference sample of 
6,000 (nearly) unrelated (pairwise relatedness <0.025) individuals of white British origin, 
randomly selected from the UK Biobank, to model patterns of LD between variants. The 
reference panel of genotypes consisted of the same 39 million variants from the HRC 
reference panel assessed in our GWAS, but with an additional quality control step to exclude 
SNPs with low imputation quality (proper-info<0.4) or deviation from Hardy-Weinberg 
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equilibrium (p<1x10-6). For each locus, we first searched ±500kb surrounding the lead SNP 
(using summary statistics from BMI unadjusted or adjusted analysis, as appropriate) to 
ensure potential long-range genetic influences were assessed. Within a region, conditionally 
independent variants that reached locus-wide significance (p<10-5) were considered as index 
SNPs for distinct association signals. If the minimum distance between any distinct signals 
from two separate loci was less than 500kb, we performed additional conditional analysis 
taking both regions (encompassing ±500kb from both ends) and reassessed the 
independence of each signal. 
 
Fine-mapping of distinct association signals with T2D susceptibility. We considered 380 of 
the 403 identified distinct signals, excluding 23 that were not amenable to fine-mapping: (i) 
19 signals with MAF<0.25%; (ii) three signals where the index variant was rare and analysed 
in <50% of the total effective sample size, defined as Ne = 4  Ncases  Ncontrols/( Ncases + 
Ncontrols); and (iii) the one signal in the major histocompatibility complex because of the 
extended and complex structure of LD across the region, which complicates fine-mapping. 
 
For each of the remaining distinct signals, we first defined a genomic region 500kb on either 
side of the index variant, considering only variants with MAF>0.25% that were reported in at 
least 50% of the total effective sample size, thus removing those that were not well imputed 
in the majority of samples. We then adopted two approaches to compute 99% credible sets 
with 99% posterior probability of containing the causal variant: (i) using a (functionally 
unweighted) Bayesian approach, with the strength of evidence for association measured 
using the Bayes’ factor in favour of association for each variant15,57; and (ii) using 
(functionally weighted) fGWAS30 that reweights the association measures by using 
information from functional genomics data.   
 
(i) Genetic credible sets. For each distinct association signal, we first calculated an 
approximate Bayes factor57 in favour of association on the basis of allelic effect sizes and 
standard errors from the meta-analysis (using BMI-unadjusted or adjusted meta-analysis, as 
appropriate). For loci with a single association signal, effect sizes and standard errors from 
unconditional meta-analysis were used. For loci with multiple distinct association signals, 
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these parameters were derived from the approximate conditional analysis adjusting for all 
other index variants in the region. Specifically, for the jth variant, 
 
𝛬𝑗 = √
𝑉𝑗
𝑉𝑗+𝜔
exp [
𝜔𝛽𝑗
2
2𝑉𝑗(𝑉𝑗+𝜔)
], 
 
where βj and Vj denote the estimated allelic effect (log-OR) and corresponding variance 
from the meta-analysis. The parameter ω denotes the prior variance in allelic effects, taken 
here to be 0.0457.   
 
We then calculated the posterior probability that the jth variant drives the association signal 
(PPA), given by 
 
𝜋𝑗 =
𝛬𝑗
∑ 𝛬𝑘𝑘
. 
 
The 99% credible set15 for each locus was then constructed by: (i) ordering all variants in 
descending order of their PPA; and (ii) including ordered variants until the cumulative PPA 
reached 0.99. The number of variants and length of the genomic region covered by each 
99% credible set was then calculated. 
 
(ii) Functionally weighted credible sets. We first tested each of the 15 chromatin states in 
human islets and coding DNA sequence separately for enrichment using genome-wide data 
with the program fGWAS30. Details on generation of the 15 chromatin states have been 
described elsewhere25. The annotation with the most significant enrichment was retained 
and tested jointly with each remaining annotation. If the most significant two annotation 
model improved the model likelihood then the two annotations in the model were retained 
and the process continued until the model likelihood did not exceed the previous iteration. 
The resulting “full” model was iteratively pruned by dropping each annotation and assessing 
the cross-validated likelihood of the reduced model (i.e. an annotation was removed from 
the “full” model if dropping it increased the cross-validated likelihood). This process resulted 
in the “best joint model”.  
 
35 
 
By default, fGWAS partitions the genome into “blocks” of 5,000 SNPs and assumes no more 
than one causal variant per block. However, for direct comparison with the “genetic” 
credible sets and to account for multiple distinct association signals within a locus, we used 
a modified approach. For T2D associated regions with no evidence of more than one distinct 
signal, we delineated 1Mb windows comprising all SNPs within 500 kb of the index variant 
and partitioned the intervening regions into ~1Mb windows. These windows were manually 
input into fGWAS using the --bed command and a separate fGWAS analysis was performed 
using only the set of annotations remaining in the “best joint model”. The genome-wide 
enrichments were used as priors in a Bayesian fine-mapping analysis implemented in fGWAS 
to calculate posterior probabilities for each SNP in the designated windows. For the 
remaining regions with evidence of two or more distinct association signals, we used the 
results from the approximate conditional analyses described above and similarly performed 
a manually partitioned fGWAS analysis. We then constructed 99% credible sets as described 
above. 
 
Association analyses with UK Biobank phenotypes. We performed targeted association 
analyses using genotype and phenotype data from electronic health records (EHRs) from the 
UK Biobank. Hierarchical phenotype codes from EHRs were curated by grouping 
International Classification of Disease, Ninth Revision (ICD-9) clinical/billing codes as 
previously described58. Only phenotype codes with 20 or more cases and with minor allele 
count of 5 or greater in cases and controls were considered eligible for analysis. Logistic 
regression analyses were performed in individuals of European ancestry for relevant 
phenotype-genotype combination adjusting for six genetic ancestry principal components, 
array, and sex. 
 
Estimating phenotypic variance explained by SNPs. We used UK Biobank samples (19,119 
T2D cases and 423,698 controls) to calculate variance explained by genome-wide significant 
variants. We ran a model regressing T2D status on all independently associated rare and low-
frequency variants, assuming an additive model (and adjusting for sex, age, array, and 6 
principal components). A separate model was run to determine the variance captured by the 
independently associated common variants. 
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Co-localisation analysis. We used publicly available eQTL results from GTEx version 7 for 
adipose, liver and skeletal tissues. Islet eQTLs were called using published imputed genotype 
and aligned RNA-seq data (.vcf and .bam files) from human pancreatic islets of 118 
individuals, downloaded from the European Genome-phenome Arichve (access number 
EGAS00001001265). RNA extraction, sequencing, and mapping, as well as DNA extraction, 
genotyping, imputation, and variant filtering was performed as described previosuly33. 
Gene-level reads were quantified using featureCounts version 1.5.0-p259, based on a 
patched version of GENCODE 19 published by the GTEx Consortium. Quantified gene level 
read counts for pancreatic islets were filtered in line with protocols used for GTEx version 7: 
only genes with at least 6 raw counts in 20% of the samples and TPM>0.1 in at least 20% of 
the samples were used for analysis. Gene-level counts for remaining genes were converted 
to counts per million and library sizes normalised using edgeR version 3.16.560, and resulting 
expression values were rank inverse normalised per-gene. Fifteen PEER factors61 were 
calculated, and cis-eQTLs were called using FastQTL version 2.062 using a cis distance of 1Mb 
and PEER factors as covariates. 
 
We performed co-localisation analysis using eCAVIAR version 2.063. Co-localisation was 
performed for each locus-tissue pair using genetic credible set variants from the locus that 
had: i) PPA>0.01, ii) correlation data from 1000G, and iii) available eQTL results from that 
tissue. Pairwise variant correlations between credible set SNPs were calculated with PLINK 
version 1.964 using the 1000 Genomes Project genotypes (phase 3, October 2014 release)16. 
Final co-localisation results were filtered to include only variant-gene pairs with significant 
eQTL effects, which were defined as associations with FDR<0.05 for islets, or published 
significant associations based on permuted p-values for GTEx. For a credible set variant, an 
eGene with co-localisation posterior probability >0.20 was considered as target gene. 
 
Estimation of genetic variance explained. We used Linkage Disequilibrium Score Regression 
(LDSC)42 to estimate the proportion of variance explained by common genetic variants for 
T2D on the liability scale. As advised by the developers, these estimates were based on 
summary statistics (without any genomic control correction) of variants restricted to the 
subset of HapMap65 variants after excluding the MHC region. Estimations were done for 
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both sex-combined and sex-specific (BMI-unadjusted) analyses, assuming population 
prevalence of 10%. 
 
Polygenic risk score analyses. Polygenic risk score (PRSs) were created in UK Biobank samples 
using raw genotype data using the software PRsice46 using the GWAS summary statistics of 
4.6M common variants from the sex-combined BMI-unadjusted T2D meta-analysis excluding 
UK Biobank samples. PRSs were created using p-value thresholds ranging from 5x10-8 to 0.5 
using LD pruning parameters of r2 0.2 to 0.8 over 250 kb windows. We then tested each PRS 
for classification performance in UK Biobank. 
 
Reporting summary. Information on experimental design is available in the accompanying 
Life Sciences Reporting Summary file. 
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Supplementary Figure 1 
Sex-differentiated analyses. 
a) Manhattan plot (top panel) of genome-wide association results for T2D (without BMI adjustment) from female-specific meta-analysis 
of up to 30,053 cases and 434,336 controls. The association p-value (on -log10 scale) for each SNP (y-axis) is plotted against the 
genomic position (NCBI Build 37; x-axis). Association signals that reached genome-wide significance (p<5x10-8) in sex-combined 
analysis are shown in purple or yellow, if novel. b) Manhattan plot (bottom panel) of genome-wide association results for T2D without 
BMI adjustment from male-specific meta-analysis of up to 41,846 cases and 383,767 controls. c) Z-score for each of the 403 distinct 
signals from male-specific analysis (y-axis) is plotted against the z-score from the female-specific analysis (y-axis). Colour of each point 
varies with –log10 gender heterogeneity p-value and diameter of the circle is proportional to sex-combined -log10 p-value. 
 
 
 
Supplementary Figure 2 
Distributions of the allele frequency, imputation score, and posterior probability of association. 
Distribution of the risk allele frequencies for all variants having >1% posterior probability of association in genetic credible set (x-axis) 
plotted against average imputation quality (y-axis). Diameter varies with the posterior probability of association assigned to each 
variant. 
 
 
 
Supplementary Figure 3 
Islet annotation overlap of variant with the highest probability in genetic credible sets. 
Number of variants with posterior probability of association >1% (x-axis) plotted against the highest posterior probability of association 
(y-axis) assigned to a variant in the credible set. Points are colour coded according to a) islet epigenome states and b) overlap with 
transcription factor binding sites. 
 
 
 
Supplementary Figure 4 
Enrichment of cross-tissue epigenetic states in T2D GWAS data.  
fGWAS log2 fold enrichment (based on joint model for each tissue) including 95% confidence intervals (x-axis) of all chromatin states (y-
axis) genome-wide. Analyses are based on the Varshney et al.1 data which combined standard epigenomic annotations for the four 
principal tissues of interest. These analyses performed separately for each tissue show some enrichment for enhancers and/or 
promoters in all tissues with strongest and most consistent enrichment observed in islets. The universally enriched “transcript” category 
refers to coding sequence which is by definition represented by the same sequence in each “tissue-specific” analysis. 1Varshney, A. et 
al. Genetic regulatory signatures underlying islet gene expression and type 2 diabetes. Proc Natl Acad Sci U S A 114, 2301-2306 
(2017). 
 
 
 
Supplementary Figure 5 
Enrichment of islet epigenetic states in T2D GWAS data. 
fGWAS log2 fold enrichment including 95% confidence intervals (x-axis) of all chromatin states (y-axis) genome-wide. 
 
 
 
Supplementary Figure 6 
Epigenome landscape of ST6GAL1 locus. 
For variants included in 99% credible set (PPA>1%) of each distinct signal at ST6GAL1 locus, following information is shown: genomic 
position of each variant (colour coded for each distinct signal; variant with highest PPA in bold); whole genome bisulphite methylation 
data (black), 4 human islet ATAC-seq tracks (green, middle), islet chromatin states (from Thurner et al.1, Pasquali et al.2, and Varshney 
et al.3); and adipose, liver and skeletal muscle chromatin states from Varshney et al.3.  
1 Thurner, M. et al. Integration of human pancreatic islet genomic data refines regulatory mechanisms at Type 2 Diabetes susceptibility 
loci. Elife 7(2018). 2 Pasquali, L. et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet 
46, 136-143 (2014). 3 Varshney, A. et al. Genetic regulatory signatures underlying islet gene expression and type 2 diabetes. Proc Natl 
Acad Sci U S A 114, 2301-2306 (2017). 
 
 
 
Supplementary Figure 7 
Epigenome landscape of ANK1 locus. 
For variants included in 99% credible set (PPA>1%) of each distinct signal at ANK1 locus, following information is shown: genomic 
position of each variant (colour coded for each distinct signal; variant with highest PPA in bold); whole genome bisulphite methylation 
data (black), 4 human islet ATAC-seq tracks (green, middle), islet chromatin states (from Thurner et al.1, Pasquali et al.2, and Varshney 
et al.3); and adipose, liver and skeletal muscle chromatin states from Varshney et al.3.  
1 Thurner, M. et al. Integration of human pancreatic islet genomic data refines regulatory mechanisms at Type 2 Diabetes susceptibility 
loci. Elife 7(2018). 2 Pasquali, L. et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet 
46, 136-143 (2014).3 Varshney, A. et al. Genetic regulatory signatures underlying islet gene expression and type 2 diabetes. Proc Natl 
Acad Sci U S A 114, 2301-2306 (2017). 
 
 
 
Supplementary Figure 8 
Epigenome landscape of TCF7L2 locus. 
For variants included in 99% credible set (PPA>1%) of each distinct signal at TCF7L2 locus, following information is shown: genomic 
position of each variant (colour coded for each distinct signal; variant with highest PPA in bold); whole genome bisulphite methylation 
data (black), 4 human islet ATAC-seq tracks (green, middle), islet chromatin states (from Thurner et al.1, Pasquali et al.2, and Varshney 
et al.3); and adipose, liver and skeletal muscle chromatin states from Varshney et al.3.  
1 Thurner, M. et al. Integration of human pancreatic islet genomic data refines regulatory mechanisms at Type 2 Diabetes susceptibility 
loci. Elife 7(2018). 2 Pasquali, L. et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet 
46, 136-143 (2014). 3 Varshney, A. et al. Genetic regulatory signatures underlying islet gene expression and type 2 diabetes. Proc Natl 
Acad Sci U S A 114, 2301-2306 (2017). 
 
 
 
 
Supplementary Figure 9 
Heritability estimates. 
Chip heritability estimates for T2D (on the liability scale) at different empirical estimates of population- and sample-level T2D 
prevalence. 
 
 
 
 
 
 
 
 
Supplementary Figure 10 
Polygenic risk score. 
Genome-wide polygenic risk score (PRS) identifies individuals with significantly increased risk of T2D. a) PRS in UK Biobank 
individuals is normally distributed with a shift towards right, observed for T2D cases. PRS is plotted on the x-axis, with values scaled to 
a mean of 0 and standard deviation of 1. b) Individuals were binned into 40 groups based on PRS, with each grouping representing 
2.5% of population. c) BMI distribution in T2D cases, within each PRS bin. 
 
 
 
 
 
Supplementary Figure 11 
Genetic correlations between T2D and biomedical-relevant traits estimated by LD score regression implemented in LDHub.  
Genetic correlations (z-score) between T2D (y-axis) and range of metabolic and anthropometric traits (x-axis) as estimated using LD 
Score regression. The genetic correlation estimates are colour coded according to phenotypic area. Allelic direction of effect is aligned 
to increased T2D risk. Size of the circle denotes the significance level for the correlation. 
 
 
 
 
Supplementary Figure 12 
Impact of BMI adjustment on genetic correlation estimates between various traits and T2D. 
Genetic correlations (z-score) between range of metabolic and anthropometric traits and T2D without BMI adjustment (x-axis) and T2D 
with BMI adjustment (y-axis) as estimated using LD Score regression. The genetic correlation estimates are colour coded according to 
phenotypic area. Allelic direction of effect is aligned to increased T2D risk. Size of the circle denotes the significance level for the 
correlation. 
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